Pub. Date : 2011 Jul
PMID : 21166756
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. | Cisplatin | solute carrier family 29 member 1 (Augustine blood group) | Homo sapiens |
| 2 | OBJECTIVE: To evaluate the expression of the human equilibrative nucleoside transporter 1 (hENT1) and excision repair cross complementing 1 (ERCC1) as possible prognostic factors for patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. | Cisplatin | solute carrier family 29 member 1 (Augustine blood group) | Homo sapiens |
| 3 | OBJECTIVE: To evaluate the expression of the human equilibrative nucleoside transporter 1 (hENT1) and excision repair cross complementing 1 (ERCC1) as possible prognostic factors for patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. | Cisplatin | solute carrier family 29 member 1 (Augustine blood group) | Homo sapiens |
| 4 | PATIENTS AND METHODS: The present study retrospectively evaluated the expression of hENT1 and ERCC1 by immunostaining in chemo-naive primary bladder tumour specimens from 40 patients with metastatic bladder cancer who received treatment with gemcitabine-cisplatin-based combination chemotherapy at Wakayama Medical University Hospital and affiliated hospitals from May 2002 to July 2009. | Cisplatin | solute carrier family 29 member 1 (Augustine blood group) | Homo sapiens |
| 5 | CONCLUSION: The data obtained in the present study show that high expression of hENT1 in tumour cells is associated with prolonged survival in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. | Cisplatin | solute carrier family 29 member 1 (Augustine blood group) | Homo sapiens |